Venture Life Group Finalizes 100,000 Share Repurchase at 69.60p Each Under Ongoing Buyback Program

Completion of Share Buyback Under Approved Programme

Venture Life Group executed a share repurchase of 100,000 ordinary shares of 0.3 pence each, continuing the buyback programme announced on 30 September 2025. The shares were purchased on the open market on 17 July 2026 through Cavendish Capital Markets Limited. The volume-weighted average price paid was 69.60 pence per share, which was both the lowest and highest price during the transaction, reflecting a single-price execution on the AIM exchange at 16:38 on the transaction date.

The repurchased shares will be held as treasury shares, a standard practice allowing the company flexibility in capital management. Treasury shares may later be cancelled, reissued to employees, or used for other corporate purposes as decided by the board. The total cost of this transaction was approximately A369,600. This buyback underscores the company’s ongoing commitment to its shareholder-approved repurchase programme, executed in compliance with AIM exchange regulations and market practices.

Capital Structure Updates After Treasury Share Acquisition

Following this repurchase, Venture Life’s capital structure now comprises 128,860,145 ordinary shares issued, with 7,556,904 held in treasury. Consequently, the total voting rights stand at 121,303,241, representing shares in active circulation. This distinction between issued shares and voting rights is essential for regulatory compliance and shareholder notification requirements under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

The voting rights figure of 121,303,241 serves as the baseline for shareholders to determine if they must disclose interests or changes in holdings per FCA regulations. This threshold-based disclosure system mandates major shareholders to report when their stakes cross specific percentage thresholds relative to total voting capital. Publishing this figure ensures transparency and accurate compliance for all market participants. The increase in treasury shares reflects the ongoing nature of the approved buyback programme, enhancing the company’s capital structure flexibility.

Venture Life’s Position in the Consumer Healthcare Market

Venture Life Group is an international consumer self-care company headquartered in the UK, specializing in products for the global self-care market. It is recognized for leadership in proactive healthy longevity, innovation, product development, and commercialization within consumer healthcare. Its diverse product portfolio spans multiple therapeutic areas: Balance Activ targets women’s intimate healthcare; Earol supports ear, nose, and throat care; Lift and Glucogel focus on energy and glucose management for hypoglycaemia treatment and prevention.

The Health & Her range addresses hormonal health across the female lifecycle, typically recommended by pharmacists or healthcare practitioners, positioning these products within trusted healthcare advisor channels rather than direct consumer marketing. Distribution is multi-channel, including health and beauty stores, pharmacies, grocery multiples, and e-commerce globally. The company maintains direct supply relationships in the UK, Ireland, and the USA, while leveraging international distribution partners in other regions to maintain brand control and margin management alongside local market expertise.

Transaction Execution and Regulatory Compliance

The share repurchase was executed on the AIM exchange (venue code AIMX) at 16:38 on 17 July 2026 through Cavendish Capital Markets Limited, the appointed broker. The transaction occurred at a single price of 69.60 pence per share, suggesting a pre-arranged block trade or a controlled market purchase. The company’s regulatory filing complies with Market Abuse Regulations and Listing Rules, disclosing aggregated and individual transaction details.

Cavendish Capital Markets Limited also serves as Venture Life’s nominated adviser and broker, providing corporate finance advisory services. The transaction was disclosed via the Regulatory News Service, ensuring equal access to information for all investors and market participants, demonstrating the company’s commitment to transparency and regulatory adherence in managing its capital structure.

Strategic Benefits of Treasury Share Holdings

Holding 7,556,904 treasury shares, approximately 5.9% of issued share capital, grants Venture Life strategic flexibility in capital management. These shares can be used for employee share schemes, management incentives, or acquisitions involving share-based consideration without needing immediate shareholder approval. Treasury shares also reduce the effective share count for earnings per share calculations without proportionally diluting voting rights, potentially enhancing EPS metrics while maintaining control.

However, investors should consider that the buyback represents a use of company cash that might otherwise have funded dividends, debt reduction, or operational investments. The board’s prioritization of buybacks indicates confidence in the company’s valuation relative to cash flow and growth prospects. The announcement does not specify the total buyback programme value or timeline for completion.

Consumer Healthcare Sector Trends and Product Portfolio Strength

Venture Life operates in a growing consumer healthcare and self-care sector driven by ageing populations, rising health awareness, and a shift toward preventative care. Its portfolio addresses key market segments: Balance Activ for women’s intimate health with high pharmacist recommendation rates; Earol for ENT care, a resilient over-the-counter market; Lift and Glucogel for energy and glucose management amid increasing metabolic health focus; and Health & Her for hormonal lifecycle support, especially perimenopause and menopause.

These products benefit from strong healthcare practitioner endorsement, reducing reliance on direct consumer advertising. The diversified multi-therapeutic product range mitigates risks associated with economic downturns or category-specific challenges. The announcement does not disclose revenue breakdown by product or geography.

Distribution Strategy and Geographic Reach

Venture Life employs a dual distribution model combining direct supply relationships in the UK, Ireland, and USA with international distribution partners elsewhere. This approach balances brand control, pricing, and stock management in key markets with local expertise and regulatory navigation in secondary markets. Products are available through health and beauty stores, pharmacies, grocery multiples, and e-commerce, ensuring broad consumer access.

The pharmacy channel is particularly important, aligning with the company’s pharmacist recommendation positioning. Grocery multiples provide impulse purchase opportunities, while e-commerce addresses growing online healthcare product demand. The announcement does not disclose sales percentages by channel or geographic contribution, limiting concentration risk analysis.

Share Price Context and Valuation Insights

The 69.60 pence per share repurchase price reflects management’s valuation of fair value relative to intrinsic worth and growth prospects. Share buybacks typically occur when boards consider shares undervalued relative to earnings potential and cash generation. Continuing repurchases at this price indicates confidence in valuation and capital management. The announcement does not provide prior share price data, price range, or forward valuation guidance.

The immediate share price impact is unclear. While buybacks reduce share count and can improve EPS, shareholder value is only created if shares are repurchased below intrinsic value. No commentary on current trading performance, market conditions, or future share price expectations was provided, limiting assessment of buyback timing effectiveness.

Regulatory Disclosure and Market Transparency

Venture Life’s disclosure of this share repurchase complies with AIM exchange regulations, including Market Abuse Regulations and Listing Rules. The announcement details transaction date, time, price, volume, executing broker, and venue, ensuring transparency and fair market conditions. Publishing voting rights post-transaction establishes the denominator for FCA disclosure thresholds, aiding shareholder compliance with notification obligations.

The company’s detailed regulatory filings reflect best practices, though no timeline or total authorisation details for the buyback programme were disclosed.

Capital Management Outlook and Shareholder Guidance

The ongoing buyback programme, initiated in September 2025, highlights a capital management strategy focused on share repurchases over alternatives like dividends or debt reduction. Holding repurchased shares as treasury preserves future flexibility for incentives, acquisitions, or other strategic uses. Treasury shares now represent a significant portion of issued capital, indicating a measured, consistent buyback pace rather than aggressive one-off purchases, reflecting steady board confidence across market conditions.

Shareholders should watch for updates on buyback pace, total capital deployed, and programme completion guidance. The announcement omits total authorisation, cumulative spend, and expected timeline. Investors should evaluate whether buybacks represent optimal capital allocation versus operational, product development, or dividend opportunities, considering the company’s financial health and growth prospects.